Mr Westberg brings nearly 30 years' finance and management experience to BONESUPPORT. He joins from Recipharm AB (publ) - one of the largest pharmaceutical contract manufacturers in the world - where he has been CFO since 2007. Prior to this he was CFO of the listed (Nasdaq Stockholm) software company Jeeves (2001-2007), and before that he held senior roles at AstraZeneca, among those Finance Director ISMO Northern Europe and Controller in Astra Japan.
Mr Westberg replaces Offer Nonhoff, who is to leave after four-and-a-half-years with the company.
Richard Davies, CEO of BONESUPPORT, said: "I am very pleased to welcome Björn to the BONESUPPORT team. He brings with him a wealth of finance and management experience that I am confident will be crucial to the future growth and development of the company. With our recent strengthening of the Board, with the appointment of Dr. Hakan Björklund as Chairman and Tone Kvåle as a Non-executive Director, and Patrick O'Donnell joining to drive our rapidly growing North American business, we are building a first rate team with the experience and talent that will help us realise the significant potential of our CERAMENT™ platform.
"I would also like to thank Offer for his dedication to BONESUPPORT over the years and wish him all the very best in future."
Mr Westberg adds: "I look forward to joining BONESUPPORT, where I am confident that my experience will be important as they grow the sales of CERAMENT BVF, CERAMENT G and CERAMENT V and invest in clinical data that will further differentiate these products in the minds of surgeons and payers. BONESUPPORT also has an exciting product pipeline, based on the unique drug eluting properties of its proprietary CERAMENT platform which will be targeting the treatment of a broader range of bone diseases. Given these strengths and the quality of the BONESUPPORT team I am confident that the Company can achieve its strategic goals."
- Ends -
Notes to Editor
BONESUPPORT has developed CERAMENT as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT BVF addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT BVF is commercially available in the U.S., EU, SE Asia and the Middle East.
CERAMENT's distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT G and CERAMENT V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.
CERAMENT G and V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT G and CERAMENT V are available in the EU.
BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT's mission is to bring people with bone and joint diseases back to an active life. The Company is based in Lund, Sweden. http://www.bonesupport.com
BONESUPPORT™ is a registered trademark.
Citigate Dewe Rogerson
David Dible, Andrea Bici, Mark Swallow
+44 (0)20 7282 2949/1050/2948
SOURCE BONESUPPORT AB